Genome-wide association studies have revealed a locus at 8p12 that is associated with breast cancer risk. Fine-mapping of this locus identified 16 candidate causal variants (CCVs). However, as these variants are intergenic, their function is unclear. To map chromatin looping from this risk locus to a previously identified candidate target gene, DUSP4, we performed chromatin conformation capture analyses in normal and tumoral breast cell lines. We identified putative regulatory elements, containing CCVs, that loop to the DUSP4 promoter region. Using reporter gene assays, we found that the risk allele of CCV rs7461885 reduced the activity of a DUSP4 enhancer element, consistent with the function of DUSP4 as a tumor suppressor gene. Furthermore, the risk allele of CCV rs12155535, located in another DUSP4 enhancer element, was negatively correlated with looping of this element to the DUSP4 promoter region, suggesting that this allele would be associated with reduced expression. These findings provide the first evidence that CCV risk alleles downregulate DUSP4 expression, suggesting that this gene is a regulatory target of the 8p12 breast cancer risk locus.
Introduction
Genome-wide association studies by the Breast Cancer Association Consortium (BCAC) and Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have previously found genetic variants at 8p12 associated with breast cancer risk [1] [2] [3] [4] . In the largest study, the rarer allele (A) of SNP rs9693444 was associated with a per-allele odds ratio (OR)=1.06 (95% CI 1.04-1.08; p=2x10 -21 ) [1] . Subsequent fine-mapping analysis of BCAC and CIMBA data at this locus revealed 16 candidate causal variants (CCVs; Supplementary Table S1), including rs9693444, which could not be statistically separated from each other using a likelihood ratio criterion of 100:1 [5] . The CCVs are located in an intergenic region ≥300 kb centromerically from DUSP4 and ≥285 kb telomerically from the microRNA MIR3148.
A major obstacle in the follow-up of GWAS loci is the identification of target genes. Indeed, INQUISIT (integrated expression quantitative trait and in silico prediction of GWAS targets) [1, 5] . In our latest fine-mapping study, INQUISIT revealed seven target genes at the 8p12 breast cancer risk locus, of which only DUSP4, was a high confidence target [5] . This prediction was partly based on evidence of long-range regulatory chromatin interactions between CCVs and the DUSP4 promoter which included: RNA polymerase II chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) data in a breast cancer cell line [6] ; Hi-C chromatin-interaction and bioinformatic analysis identifying an enhancer coincident with CCVs that interacts with the DUSP4 promoter [7] ;
and capture Hi-C data from breast cancer cell lines [8] .
The chromatin interaction data identified through INQUISIT suggest that CCVs could regulate DUSP4 expression through enhancer-promoter interactions. This may be a common mechanism through which GWAS variants act (reviewed in [9] ). Indeed, at a number of breast cancer GWAS risk loci, we have previously shown that CCVs in regulatory elements loop to promoters and regulate their activity [1, 10, 11] . In the current study, we map long-range chromatin interactions between the 8p12 risk locus and the promoter region of DUSP4. We provide evidence that a CCV, coincident with a putative regulatory element (PRE) that interacts with DUSP4, can regulate DUSP4 promoter activity. Furthermore, we find a CCV in a different PRE that is associated with allele-specific chromatin looping to the DUSP4 promoter region. These data suggest strongly that DUSP4 is a target gene of breast cancer risk variation at the 8p12 locus.
Results

Chromatin conformation capture (3C) analyses confirm that the 8p12 risk locus physically interacts with the promoter region of DUSP4
To explore chromatin interactions between the 8p12 risk locus and the DUSP4 promoter in breast cells, chromatin conformation capture (3C) analyses were conducted in breast cancer (MCF-7 and T47D) and normal mammary epithelial (Bre-80) cell lines. Some level of interaction with the DUSP4 promoter was observed in all three cell lines across the 3C restriction fragments at the risk locus (Figure 1) . Notably, this broad level of activity is not often observed in 3C analyses. For example, the 2q35 and 5q11.2 breast cancer risk loci are considerably closer (≤100kb) to corresponding promoter targets than 8p12 CCVs are to the DUSP4 promoter region, yet many restriction fragments at these loci have no observable promoter interaction [10, 11] . At the 8p12 locus, five 3C restriction fragments (#6, #8, #10, #11 and #12) with Hi-C and/or ChIA-PET evidence of chromatin looping to the DUSP4 promoter demonstrated peaks of interaction in the breast cell lines (Figure 1) , highlighting three fragments (#6, #11 and #12) which contain CCVs (three, two and three, respectively) for further analysis. 
CCV rs7461885 reduces the enhancer activity of PRE1 on the DUSP4 promoter
From analysis of the 3C, ChIA-PET and epigenetic data at the 8p12 locus (Figure 1) , CCVs in three putative regulatory elements (PRE1-3) were prioritized for reporter gene analyses to determine their effects on DUSP4 promoter activity (Figure 2) . PRE1, containing three CCVs, significantly enhanced DUSP4 promoter activity by 2.3-2.5 fold in Bre-80 and MCF-7 cells, respectively (Figure 2A and B) .
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In these two cell lines, the risk-associated allele of rs7461885, whether as a single variant or in a haplotype with the risk alleles of two other CCVs, significantly reduced the PRE1 enhancer activity by 1.3-1.5 fold (Figure 2A and B) . Analysis of rs7461885 using HaploReg [12] did not indicate any evidence for transcription factor motifs or binding; however, this variant is located in active histone marks (H3K4Me1, H3K4Me2 and H3K27Ac) in normal mammary epithelial cells (Figure 1) . PRE2, containing two CCVs, significantly enhanced DUSP4 promoter activity by 2.5-2.7 fold in MCF-7 and Bre-80 cells, respectively, but neither CCV affected this enhancer activity, nor did the haplotype containing both risk alleles (Figure 2C and D) . PRE3, containing one CCV, significantly enhanced promoter activity by 1.3 fold in Bre-80 cells but had no significant effect in MCF-7 cells (Figure 2E and F). The CCV in PRE3 did not affect promoter activity in either cell line (Figure 2E and F) .
Reporter assays were also performed in T-47D cells but neither PREs nor CCVs significantly affected DUSP4 promoter activity (Supplementary Figure S1 ). 
CCV rs12155535 (PRE2) is associated with allele-specific looping to the DUSP4 promoter region
Of the three breast cell lines used in the 3C assay, only one (Bre-80) was heterozygous for CCVs and thus amenable for allele-specific 3C analysis. After assessing CCVs in the PREs and their proximity to the 3C restriction sites, we found that only PRE2 could be analysed for allele-specific looping using PCR-based Sanger sequencing. Using Bre-80 3C libraries, we found that there was a reduction of the risk (C) allele of CCV rs12155535 in PRE2 interactions (Figure 3) , compared to the Bre-80 genomic DNA control. This finding indicates that the risk allele was negatively correlated with the PRE2 enhancer-DUSP4 promoter region interaction, providing evidence that risk allele may be associated with diminished DUSP4 expression through a reduction in enhancer looping to the DUSP4 promoter region. 
Discussion
In this study, we used genetic approaches to identify functional CCVs and regulatory targets at the 8p12 breast cancer risk locus. Firstly, we performed 3C in normal and breast cancer cell lines to map chromatin interactions between PREs, containing CCVs, and the DUSP4 promoter region. Although we cannot rule out interactions with other genes at this locus, these findings were consistent with available chromatin interaction analyses, and no other high-confidence targets were predicted by the INQUISIT pipeline in this region [5] . Secondly, we prioritised three PREs with evidence of interaction with the DUSP4 promoter region (i.e. PRE1-3) for reporter gene analyses. These assays demonstrated that PRE1 and PRE2 acted as enhancers of DUSP4 promoter activity in both normal and tumoral breast cell lines. PRE1 and PRE2 are located in areas of active chromatin as indicated by the presence of transcription factor binding and strong histone peaks characteristic of enhancers (Figure 1) . CCVs in PRE1-3 were tested for effects on the DUSP4 promoter and the risk allele of CCV rs7461885 was found to repress the DUSP4 enhancer activity of PRE1. It is possible that other CCVs at the 8p12 locus, which were not assessed in the reporter gene assays, may also regulate DUSP4; however, the available epigenetic data suggested these variants were less likely to be functional.
Finally, we performed an allele-specific 3C analysis and found that the risk allele of CCV rs12155535 was present less often in PRE2-DUSP4 promoter region interactions in comparison with the protective allele. As the reporter gene assays had demonstrated that PRE2 acted as a DUSP4 Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 24 November 2019 doi:10.20944/preprints201911.0271.v1 enhancer, the association of the rs12155535 risk allele with reduced PRE2-DUSP4 interaction frequency was consistent with the negative effect of the risk allele of rs7461885 on DUSP4 promoter activity. The 3C and reporter gene findings indicate that DUSP4 is a likely target gene and is downregulated by risk associated alleles at the 8p12 locus. However, expression quantitative trait loci data from mammary tissue (n=396) in the Genotype Tissue Expression database (version 8; https://gtexportal.org/home/ accessed on 09/10/2019) and tumour tissue (n=799) in The Cancer Genome Atlas eQTL browser (https://albertlab.shinyapps.io/tcga_eqtl/ accessed on 9/10/2019) provided no evidence that CCVs associated with DUSP4 expression in normal or tumour breast tissue. A lack of CCV eQTLs at cancer risk GWAS loci is a common finding [10, 11, 13, 14] and could be due to several issues: i) the available eQTL studies may not have enough statistical power to detect modest effects on DUSP4 expression; ii) the tissues used, especially tumour tissue, are heterogeneous, containing multiple cell types, and thus may mask CCV effects on DUSP4 expression that occur in specific cell types; and iii) CCVs could have development or context specific effects on DUSP4 expression that are not captured by the available studies.
DUSP4 encodes a nuclear dual specificity protein phosphatase which inactivates ERK, JNK and p38 mitogen-activated protein kinases [15] and may also play a regulatory role in gene expression through chromatin binding [16] . DUSP4 is frequently deleted in breast tumours [17, 18] and cancer cell lines [19] . DUSP4 knockdown enhances the formation of breast cancer stem cells [16, 20] and increases the invasive ability of ER-positive breast cancer stem cells [20] . In ER-negative breast cancer cells, DUSP4 knockdown increases the formation of mammospheres and the expression of cancer stem cell promoting cytokines [19] . Thus, the literature indicates that DUSP4 acts as a tumor suppressor in breast cancer which is compatible with our finding of its negative regulation by a breast cancer risk allele.
Materials and Methods
Cell culture
Cell lines were stored in liquid nitrogen vapour phase with Mycoplasma testing and short tandem repeat profiling performed for cell authentication prior to storage. The immortalised mammary epithelial Bre-80 cell line was cultured as previously described [21] . The breast cancer cell lines MCF-7 and T-47D were cultured in RPMI 1640 medium supplemented with fetal calf serum, penicillin/streptomycin and 10 g/ml insulin. All cell lines were cultured at 37°C in a humidified 5% CO2 atmosphere.
3C analysis
3C libraries were generated from breast cell lines using EcoRI as previously described [22] . 3C interactions were quantified by qPCR with primers designed with the EcoRI restriction fragments spanning the 8p12 risk locus ( Supplementary Table S2 ). qPCR was performed using a RotorGene 6000 with a reaction mix containing MyTaq HS DNA polymerase and the addition of 5 mM Syto9. Thermal cycling was performed with an annealing temperature of 66 o C (20 s) and extension at 72 o C (30 s). Three independent 3C libraries were analysed by qPCR with each experiment quantified in duplicate. Two BAC clones (RP11-56L5 and RP11-833O14: BACPAC Resource Center) encompassing the DUSP4 promoter region and the 8p12 breast cancer risk locus were used to create a library of ligation products to determine 3C primer efficiencies for normalization.
Reporter gene vector construction
A DUSP4 promoter luciferase reporter construct was generated by inserting a 1650 bp of PCR-amplified DNA, containing the DUSP4 transcription start (chr8:29,207,878-29,209,527; GRCh37), site into the KpnI and HindIII sites of a pGL3-Basic construct. The pGL3-Basic construct had been engineered to include AgeI and SbfI sites downstream of the luciferase gene [6] . A 2464 bp PRE1 region (chr88:29,527,323-29,530,033) was PCR generated using primers engineered with Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 24 November 2019 doi:10.20944/preprints201911.0271.v1
BamHI and SalI sites for insertion downstream of the Firefly luciferase gene. A 980 bp PRE2 region (chr8:29522728-29523707) and a 981bp PRE3 region (chr88:29508759-29509739) were synthesised with terminal AgeI/SalI and BamHI/SbfI sites, respectively (Integrated DNA Technologies, Singapore) for cloning into the DUSP4 promoter construct. For PRE1, the allelic variants of CCVs were introduced by overlap extension PCR. For PRE2 and 3, constructs containing allelic variants were also synthesised by Integrated DNA Technologies and cloned as above. All constructs were Sanger sequenced (QIMR Berghofer sequencing facility) to confirm variant incorporation. All PCR and sequencing primers are listed in Supplementary Table S3 .
Bre-80, MCF-7 and T-47D cells were transfected with equimolar amounts of luciferase reporter constructs and 50 ng of the Renilla luciferase pRL-SV40 construct with Lipofectamine 2000. The total amount of transfected DNA was kept constant at 600 ng for each construct by adding pUC19 as a carrier plasmid. Luciferase activity was measured 24 h post-transfection by the Dual-Glo Luciferase Assay System. To correct for variation in transfection efficiency or cell lysate preparation, Firefly luciferase activity was normalised to that of the Renilla luciferase. All DUSP4 promoter constructs had great activity than the negative control (empty pGL3-Basic construct). Data were log-transformed and statistical significance was assessed by two-way ANOVA followed by Dunnett's multiple comparisons test in GraphPad Prism (version 7.02).
Allele-specific 3C analysis
DNA was amplified by PCR of two independent Bre-80 3C libraries using the DUSP4 promoter bait primer and a reverse primer specific to the PRE2 fragment containing rs12155535 ( Supplementary Table S2 ). The region containing rs12155535 was also amplified from Bre-80 genomic DNA as a control. Sanger sequencing (QIMR Berghofer sequencing facility) was performed to determine the alleles present in the interacting PRE2 fragment.
Conclusions
We have found the first evidence that breast cancer risk variation at the 8p12 locus downregulates DUSP4 promoter activity and is negatively correlated with long-range chromatin looping interactions with the DUSP4 promoter region. These findings are consistent with the role of DUSP4 as a tumor suppressor in breast cancer and suggest that the effects of CCVs on breast cancer risk may be mediated by a reduction in DUSP4 expression.
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